Pfizer's bapineuzumab based on Intellect Neuroscience Antisenilin Platform (license agreement).
Intellect Neuroscience (74 Patents) develops next generation drugs for neurodegenerative disorders;
Intellect is the first company to develop antibody drug conjugates (ADCs) in which amyloid clearing antibodies are empowered by chemically linking them to molecules that offer neuroprotection, creating a single drug; especially N01-OX2 (Conjumab-A Platform) is being developed by Lonza for the treatment of AD ($8 billion annually) and AMD ( $4 billion annually). That's a fact!
Sentiment: Strong Buy